Oculis Holding (OCS) has recently been awarded a Buy rating by Stifel Nicolaus analyst Annabel Samimy, a decision influenced by the promising clinical results of its drug OCS-05 in the treatment of acute optic neuritis (AON). A proof-of-concept study highlighted the drug's potential neuroprotective effects, showing significant improvements in both anatomical and functional outcomes. Notably, the study achieved its primary safety endpoint, with improvements in GCIPL and RNFL thickness, and enhanced visual acuity sustained over a six-month period.
OCS-05 also demonstrated a positive safety profile, with no significant adverse events reported. Its potential to reduce relapses in CNS inflammatory conditions further underscores its therapeutic promise. The FDA's clearance for its investigational new drug (IND) application paves the way for regulatory trials for AON and exploration in other neuro-ophthalmic and neurological conditions.
This development, combined with the unmet need in AON treatment and the potential market size, underpins the Buy rating for Oculis Holding's stock. Annabel Samimy, who covers the Healthcare sector, has an average return of 4.8% and a 43.58% success rate on recommended stocks, according to TipRanks. Additionally, H.C. Wainwright recently reiterated a Buy rating on the stock with a $30.00 price target.
Oculis Holding (OCS) is described as a European Biotech Acquisition Corp, a blank check company.
